Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep;15(9):284.
doi: 10.1007/s13205-025-04451-x. Epub 2025 Aug 6.

Bridging the molecular and clinical aspects of resveratrol in Alzheimer's disease: a review

Affiliations
Review

Bridging the molecular and clinical aspects of resveratrol in Alzheimer's disease: a review

Liju Susan Mathew et al. 3 Biotech. 2025 Sep.

Abstract

Alzheimer's disease (AD) is a progressive brain disorder that affects neurological functioning specifically targeting cognition, memory and behaviour. Pathology starts with the accumulation of tau proteins which on phosphorylation can be destructive for brain function. With gold standard drugs like Donepezil, there have been several attempts made to discover adjuvant therapeutic molecules such as plant-based products that could not only ease the ill-toward effects of these drugs, but also lead to the betterment of the patients suffering from AD. These are crucial in the management of patients of AD, by associations with psychological vulnerabilities and the overall loss of health of such individuals 'Resveratrol' is one such plant-based molecule which is a stilbene polyphenol present in many of the commonly occurring plants. Resveratrol is reported to have anti-oxidant and anti-inflammatory properties which brings about the neuroprotection. Several studies have also been conducted that targets the signalling cascades involved during the progression of AD. This review attempts to give a collective information of its properties, its synthesis, metabolism and mechanisms that could drive researchers forward for its therapeutic applications during the treatment of Alzheimer's disease.

Keywords: Alzheimer’s disease; Anti-inflammatory; Anti-oxidant; Neurodegeneration; Neuroprotective; Resveratrol.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors have no competing interests to declare that are relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Schematic representation of resveratrol and its neuroprotective effect against Alzheimer's disease progression through the regulatory signaling pathway
Fig. 2
Fig. 2
Representation of mechanism of anti-oxidant effect of resveratrol on AD

Similar articles

  • The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C, Schatzberg AF. DeBattista C, et al. Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
  • Short-Term Memory Impairment.
    Cascella M, Al Khalili Y. Cascella M, et al. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31424720 Free Books & Documents.
  • Selegiline for Alzheimer's disease.
    Birks J, Flicker L. Birks J, et al. Cochrane Database Syst Rev. 2003;(1):CD000442. doi: 10.1002/14651858.CD000442. Cochrane Database Syst Rev. 2003. PMID: 12535396
  • Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.
    Mukherjee A, Roy D, Chakravarty A. Mukherjee A, et al. Curr Neurol Neurosci Rep. 2025 Jul 1;25(1):45. doi: 10.1007/s11910-025-01432-8. Curr Neurol Neurosci Rep. 2025. PMID: 40591029 Review.
  • Donepezil for dementia due to Alzheimer's disease.
    Birks JS, Harvey RJ. Birks JS, et al. Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3. Cochrane Database Syst Rev. 2018. PMID: 29923184 Free PMC article.

References

    1. An L, Shen Y, Chopp M, Zacharek A, Venkat P, Chen Z, Li W, Qian Y, Landschoot-Ward J, Chen J (2021) Deficiency of endothelial nitric oxide synthase (eNOS) exacerbates brain damage and cognitive deficit in a mouse model of vascular dementia. Aging Dis 12(3):732–746. 10.14336/AD.2020.0523 - PMC - PubMed
    1. Assefa BT, Tafere GG, Wondafrash DZ, Gidey MT (2020) The bewildering effect of AMPK activators in Alzheimer’s disease: review of the current evidence. Biomed Res Int 2020:9895121. 10.1155/2020/9895121 - PMC - PubMed
    1. Austin SA, Santhanam AV, Katusic ZS (2010) Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ Res 107:1498–1502 - PMC - PubMed
    1. Azargoonjahromi A, Abutalebian F (2024) Unraveling the therapeutic efficacy of resveratrol in Alzheimer’s disease: an umbrella review of systematic evidence. Nutr Metab 21(1):15. 10.1186/s12986-024-00792-1 - PMC - PubMed
    1. Bartra C, Yuan Y, Vuraić K, Valdés-Quiroz H, Garcia-Baucells P, Slevin M, Pastorello Y, Suñol C, Sanfeliu C (2024) Resveratrol activates antioxidant protective mechanisms in cellular models of Alzheimer’s disease inflammation. Antioxidants 13(2):177. 10.3390/antiox13020177 - PMC - PubMed

LinkOut - more resources